Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
An announcement from Ascendis Pharma ( (ASND) ) is now available.
Ascendis Pharma announced strategic initiatives and financial expectations at the J.P. Morgan Healthcare Conference, highlighting their focus on becoming a leader in endocrinology rare diseases. The company projects significant revenue growth with their approved products and pipeline candidates, aiming to achieve blockbuster status for multiple therapies by 2030. Their expansion strategy includes leveraging their TransCon technology across various therapeutic areas and forming strategic partnerships, which positions them for long-term innovation and market leadership.
More about Ascendis Pharma
Ascendis Pharma is a biopharmaceutical company focusing on the development of innovative therapies for endocrinology rare diseases. Their primary products include SKYTROFA for growth hormone deficiency, YORVIPATH for hypoparathyroidism, and TransCon CNP for achondroplasia. The company is expanding its TransCon technology platform for broader therapeutic applications, including oncology and metabolic diseases, through partnerships and internal development.
YTD Price Performance: -6.38%
Average Trading Volume: 415,936
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $7.72B
Find detailed analytics on ASND stock on TipRanks’ Stock Analysis page.
